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Design
Total population /
SAT vs. DAPT
Mean
age Male
Second
antiplatelet
Duration
of DAPT Follow-up Valve
Durand 2014 Prospective
cohort
292 / 164 vs 128 83.6 y 48% Clopidogrel 1 mo 30 days CoreValve,
SAPIEN
Poliacikova 2013 Retrospective
cohort
149 / 91 vs 58 82 y 54% Clopidogrel 6 mo 30 days,
6 mo
CoreValve
SAT-TAVI 2014 RCT 120 / 60 vs 60 81.1 y 33% Clopidogrel or
ticlopidine
6 mo 30 days,
6 mo
SAPIEN XT
Ussia 2011 RCT 79 / 39 vs 40 81 y 46% Clopidogrel 3 mo 30 days,
6 mo
CoreValve
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BACKGROUND There are no reports on a large-scale randomized trial
exploring optimal dual antiplatelet therapy (DAPT) duration after
biodegradable polymer sirolimus-eluting stent (BP-SES) implantation.
We sought to report the 18month follow-up of randomized substudy
of the prospective I-LOVE-IT 2 trial, which compared safety and efﬁ-
cacy between patients receiving 6- vs. 12-month DAPT after implan-
tation of a novel BP-SES.
METHODS In the prospective randomized I-LOVE-IT 2 trial, 1829 pa-
tients who were allocated to the BP-SES group were also randomized
to receive either 6-month (n¼909) or 12-month DAPT (n¼920). The
endpoints of this substudy included 18-month TLF, and 18-month net
adverse clinical and cerebral events (NACCE), a composite of all-cause
death, all MI, stroke, and major bleeding (Bleeding Academic Research
Consortium [BARC] type 3 bleeding).
RESULTS At 18 months, there was no difference in TLF between 6-
month DAPT and 12-month DAPT groups (7.5% [68/909] vs. 6.3% [58/
920], Log-rank p¼0.32). The 18-month incidence of NACCE were also
similar between the groups (7.8% [72/909] versus 7.3% [67/920], Log-
rank p¼0.60), or its individual endpoint components. Landmark an-
alyses also showed that there was no signiﬁcant difference of NACCE
through 6-18 months between the groups (Log-rank p ¼ 0.32). No
deﬁnite/probable stent thrombosis occurred between 6 and 18 months
in either group; however, there was arithmetically higher all-cause
mortality in the 12-month group compared to the 6-month group
(0.7% vs. 1.3%, p¼0.16) in the same time interval.
CONCLUSIONS The present study indicated noninferiority in safety
and efﬁcacy of 6- vs. 12-month DAPT after implantation of a novel BP-
SES and low 18-month stent thrombosis in both treatment arms.
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BACKGROUND Major bleeding episodes or strokes can occur in up to 25%
of transcatheter aortic valve replacement (TAVR). Although guidelines
recommend dual antiplatelet therapy (DAPT) up to 6 months, they also
recognize there is a lack of evidence comparing antiplatelet strategies in
TAVR. Previous studies were not powered for individual, but rather com-
posite end-points. We aimed to perform a meta-analysis comparing single
antiplatelet therapy (SAT) to DAPT in TAVR.
METHODS PubMed, EMBASE, Cochrane, and conference abstracts were
searched for observational and randomized studies that directly compared
SAT to DAPT in patients undergoing TAVR. Odds-ratios of safety and ef-
ﬁcacy outcomes were computed using random or ﬁxed-effects models.
Heterogeneity was examined with Cochran Q test and I2 statistics. Meta-
analysis statistics were performed with Review Manager 5.1.
RESULTS Four studies and 640 patients were included, of whom 354
(55%) received SAT. In the DAPT group, two antiplatelet agents were
given for up to 6 months (Table 1). In a 30-day follow-up, SAT was
associated with a decreased incidence of major vascular
complications (OR 0.53; p¼0.07), any vascular complication (OR
0.42; p<0.01), major bleeding (OR 0.27; p<0.01; Figure 1), life-
threatening bleeding (OR 0.41; p¼0.02), and any bleeding episode
(OR 0.44; p¼0.03). There were no signiﬁcant differences between
SAT and DAPT in all-cause mortality (p¼0.57), cardiovascularmortality (p¼0.99), major stroke (p¼0.42), or any stroke/TIA
(p¼0.64). Similar results were observed in the 6 month follow-up.CONCLUSIONS This meta-analysis suggests that SAT is safer than
DAPT in terms of vascular complications and major or life-threatening
bleeding episodes after TAVR. Further, our results indicate that a
single antiplatelet agent is as effective as DAPT in the prevention of
cerebrovascular events. Our study is hypothesis-generating; larger
randomized trials are warranted to conﬁrm these ﬁndings.
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BACKGROUND In previous unblinded trials of renal denervation
(RDN), the reduction in blood pressure (BP) was stable or further
increased over time. The SYMPLICITY HTN-3 trial is the ﬁrst ran-
domized blinded controlled trial of RDN (N¼364) vs. sham control
(N¼171) where both the patient and BP assessor were blinded to
treatment allocation until assessment of the 6-month primary
endpoint. Patient behavior speciﬁc to drug adherence was believed to
be one important factor underlying the marked 6-month BP reduction
seen in the control arm, supported by changes in ambulatory and
ofﬁce BP measurement at 12 months when subjects were unblinded.
Long-term (24-month) outcomes will provide further insights into
whether BP trends seen in both the RDN and control cohorts at 12
months persist or are accentuated.
METHODS The SYMPLICITY HTN-3 trial enrolled subjects with ofﬁce
systolic BP 160 mm Hg despite being on an average of w5 antihy-
pertensive medications, including a diuretic, at least 3 of which were
at maximally tolerated doses. While the 6-month primary safety
endpoint was met, ofﬁce and ambulatory BP did not differ between
RDN and sham groups in part due to marked BP reduction in the
control group. After 6 months, subjects were unblinded and those in
the sham group meeting eligibility requirements could undergo RDN
(crossover group) while some subjects chose not to undergo RDN or
were not eligible (non-crossover group).
